Pilocutaneous syndrome of menopause (PSM) is a proposed clinical entity paralleling GSM and MSM: the constellation of hair and skin changes driven by menopausal hormone loss, declining estrogen and the resulting relative androgen excess. Its features are dryness, thinning, laxity, wrinkling, dyspigmentation, hirsutism, hair thinning and delayed healing.
What is happening?
Estrogen supports collagen production, skin thickness, moisture retention, blood flow and repair. As estrogen falls, the dermis loses collagen, elastin and hyaluronic acid. Skin becomes thinner, drier and less elastic.
The fall in collagen is steep. Around 30% of skin collagen is lost in the first five years after menopause. That loss tracks the time since estrogen declined more closely than chronological age.
Androgen levels fall more slowly than estrogen. The result is a relative androgen excess, even when androgen levels are normal. At hair follicles that shift causes scalp hair to thin and coarse hair to grow on the chin, upper lip and jaw.
The name comes from Latin roots: pilus, hair, and cutis, skin. It is designed to sit alongside the established nomenclature of menopausal medicine. PSM places the cutaneous signature of menopause beside its genitourinary counterpart (GSM) and its musculoskeletal counterpart (MSM).
How long it lasts
Changes can begin in perimenopause, as estrogen starts to fluctuate. They usually become most noticeable in the first few years after the final period, when collagen loss is fastest.
PSM is not a phase that ends. Without treatment, the underlying changes continue, more slowly, throughout postmenopause. Early recognition therefore matters more than waiting for symptoms to settle.
Common symptoms
Skin changes include dryness, itching, thinning, loss of firmness and laxity, deeper wrinkling, and uneven pigmentation such as age spots or melasma. Cuts, grazes and surgical wounds may take longer to heal, and skin may bruise or tear more easily.
Hair changes include diffuse thinning across the crown, a widening parting, increased shedding, and drier, more brittle hair. Many women also notice new coarse hairs on the chin, upper lip or jawline.
These changes are common. In one survey, 82% of menopausal women reported hair symptoms, most often thinning. Up to half of postmenopausal women experience some degree of unwanted facial hair.
Because skin and hair change with age anyway, these features are often put down to ageing alone. The PSM framework recognizes that hormone loss accelerates them, and that some respond to treatment aimed at that cause.
Diagnosis
There is no test for PSM. As a proposed entity it is recognized from the pattern of skin and hair changes alongside menopausal status, not from a single finding.
Other causes are worth excluding, particularly when changes are sudden or severe. For hair thinning these include thyroid disease, iron deficiency, recent illness or stress, and some medicines. For eczema-like dryness or itch, they include skin conditions that need their own treatment.
Rapid-onset excess hair growth, deepening of the voice or new acne warrant specific investigation. These can point to a raised androgen level rather than the relative excess seen in PSM.
Management options
Skin care basics include gentle, fragrance-free cleansers, a rich moisturizer applied to damp skin, and daily broad-spectrum sunscreen. Sun protection limits further collagen loss and pigmentation.
Topical retinoids stimulate collagen production and can improve fine lines and firmness. They can irritate drier menopausal skin, so they are usually introduced gradually.
For scalp hair thinning, minoxidil has the strongest evidence and is available as a topical or, on prescription, oral treatment. Anti-androgen medicines are sometimes used under specialist guidance.
Unwanted facial hair can be managed with shaving, waxing, threading, laser or electrolysis, or a prescription cream that slows growth.
Menopausal hormone therapy improves skin hydration, elasticity and collagen content. Evidence for its effect on hair loss is limited. Suitability depends on personal and family history, so it requires individual assessment.
When to seek medical advice
- Hair loss that is sudden, patchy, or comes out in clumps
- Excess hair growth that develops quickly, or comes with a deepening voice or new acne
- A new or changing mole, or a sore or patch that does not heal within a few weeks
- Itching that is severe, widespread or disturbs sleep, particularly without a visible rash
- Hair thinning with fatigue, feeling cold, or weight change
Frequently asked questions
Pilocutaneous syndrome of menopause is a proposed name for the hair and skin changes driven by menopausal hormone loss. It is modelled on GSM and MSM, and covers dryness, thinning, laxity, wrinkling, pigmentation change, facial hair, hair thinning and slower healing.
It combines the Latin pilus, hair, and cutis, skin. The name mirrors the Latin-rooted terms used elsewhere in menopausal medicine.
Estrogen supports collagen, hyaluronic acid and the skin barrier. When it falls, skin holds less water and loses collagen, so it becomes drier, thinner and less elastic.
Yes. Falling estrogen and a relative androgen excess can shrink scalp follicles. This causes diffuse thinning, usually at the crown and parting, rather than bald patches.
Estrogen falls faster than androgens. The relative androgen excess can turn fine facial hair into coarser, darker hair, most often on the chin and upper lip.
It accelerates them. Around 30% of skin collagen is lost in the first five years after menopause, which reduces firmness and deepens lines.
All three describe effects of menopausal hormone loss on one body system. GSM covers the genital and urinary tract, MSM the muscles, bones and joints, and PSM the skin and hair.
